Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: A cohort study

International Journal of Cancer

Volumn 128, Issue 2, 2011, Pages 433-439

  Kosunen, Timo U ^a   Pukkala, Eero ^b,c   Sarna, Seppo ^d   Seppälä, Kari ^e   Aromaa, Arpo ^f   Knekt, Paul ^f   Rautelin, Hilpi ^a,d,g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^g UPPSALA UNIVERSITY   (Sweden)

Author keywords

eradication therapy; gastric cancer; Helicobacter pylori

Indexed keywords

ADULT; AGED; ANTIBODY TITER; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; ERADICATION THERAPY; FEMALE; FINLAND; FOLLOW UP; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; SEROLOGY; SEX DIFFERENCE; STANDARDIZED INCIDENCE RATIO; STOMACH CANCER;

ADULT; AGED; ANTIBODIES, BACTERIAL; COHORT STUDIES; FEMALE; FINLAND; FOLLOW-UP STUDIES; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; MALE; METAPLASIA; MIDDLE AGED; STOMACH NEOPLASMS;

EID: 78649549660     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25337     Document Type: Article

References (38)

1. Blaser MJ,. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990; 161: 626-33.
2. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK,. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-31.
3. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ,. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325: 1132-6.
4. International Agency for Research on Cancer monographs on the evaluation of carcinogenic risk factors in humans. Schistosomes, liver flukes and Helicobacter pylori. Lyon: IARC, 1994, 61. 177-241.
5. Helicobacter and Cancer Collaborative Group (Writing group: Webb PM, Law M, Varghese C, Forman D). Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347-53.
6. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG,. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-7.
7. Hansen S, Vollset SE, Derakhshan MH, Fyfe V, Melby KK, Aase S, Jellum E, McColl KE,. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007; 56: 918-25.
8. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ,. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008; 134: 945-52.
9. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ, Jr., Saeed ZA, Malaty HM,. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992; 116: 705-8.
10. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ,. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004; 53: 1244-9.
11. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P,. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54: 1536-40.
12. You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, Crystal-Mansour S, Pee D, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974-83.
13. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-94.
14. Yanaoka K, Oka M, Ohata H, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, Inoue I, Iguchi M, Maekita T, Ueda K, Utsunomiya H, et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer 2009; 125: 2697-703.
15. de Vries AC, Kuipers EJ, Rauws EAJ,. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol 2009; 104: 1342-5.
16. Kato M, Asaka M, Nakamura T, Azuma T, Tomita E, Kamoshida T, Sato K, Inaba T, Shirasaka D, Okamoto S, Takahashi S, Terao S, et al. Helicobacter pylori eradication prevents the development of gastric cancer-results of a long-term retrospective study in Japan. Aliment Pharmacol Ther 2006; 24 (Suppl. 4): 203-6.
17. Takenaka R, Okada H, Kato J, Makidono C, Hori S, Kawahara Y, Miyoshi M, Yumoto E, Imagawa A, Toyokawa T, Sakaguchi K, Shiratori Y,. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther 2007; 25: 805-12.
18. Ogura K, Hirata Y, Yanai A, Shibata W, Ohmae T, Mitsuno Y, Maeda S, Watabe H, Yamaji Y, Okamoto M, Yoshida H, Kawabe T, et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol 2008; 42: 279-83.
19. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y,. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005; 100: 1037-42.
20. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M,; Japan Gast Study Group. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-7.
21. Fuccio L, Zagari RM, Minardi ME, Bazzoli F,. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007; 25: 133-42 (review).
22. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F,. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151: 121-8 (review). Correction: Ann Intern Med 2009; 151: 516.
23. Kosunen TU, Seppälä K, Sarna S, Sipponen P,. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992; 339: 893-5.
24. Lerang F, Haug JB, Moum B, Mowinckel P, Berge T, Ragnhildstveit E, Bjørneklett A,. Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication. Scand J Gastroenterol 1998; 33: 710-5.
25. Rautelin H, Kosunen TU,. Helicobacter pylori in Finland. Ann Med 2004; 36: 82-8 (review).
26. Kosunen TU, Aromaa A, Knekt P, Salomaa A, Rautelin H, Lohi P, Heinonen OP,. Helicobacter antibodies in 1973 and 1994 in the adult population of Vammala, Finland. Epidemiol Infect 1997; 119: 29-34.
27. Teppo L, Pukkala E, Lehtonen M,. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994; 33: 365-9.
28. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT,. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009; 137: 1641-8.
29. Kamada T, Hata J, Sugiu K, Kusunoki H, Ito M, Tanakas S, Inoue K, Kawamura Y, Chayama K, Haruma K,. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther 2005; 21: 1121-6.
30. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13 (review).
31. Weiderpass E, Pukkala E,. Time trends in socioeconomic differences in incidence rates of cancers of gastro-intestinal tract in Finland. BMC Gastroenterol 2006; 6: 41.
32. Graham DY, Malaty HM, Evans DG, Evans DJ, Jr., Klein PD, Adam E,. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991; 100: 1495-501.
33. Kokkola A, Rautelin H, Puolakkainen P, Sipponen P, Färkkilä M, Haapiainen R, Kosunen TU,. Positive result by serology indicates active Helicobacter pylori infection in patients with atrophic gastritis. J Clin Microbiol 1998; 36: 1808-10.
34. Ekström AM, Held M, Hansson LE, Engstrand L, Nyrén O,. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001; 121: 784-91.
35. Kokkola A, Kosunen TU, Puolakkainen P, Sipponen P, Harkonen M, Laxen F, Virtamo J, Haapiainen R, Rautelin H,. Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS 2003; 111: 619-24.
36. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T, Omata M,. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54: 764-8.
37. Knekt P, Teppo L, Aromaa A, Rissanen H, Kosunen TU,. Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int J Cancer 2006; 119: 702-5.
38. Correa P,. Human gastric carcinogenesis: a multistep and multi-factorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-40.